Low-Grade Glioma, NOS

This study analyzed 159 patients with secondary glioblastoma (sGBM) and confirmed that the PTPRZ1-MET fusion is a recurrent oncogenic driver associated with significantly shorter overall and progression-free survival. Researchers identified 359 upregulated genes in fusion-positive tumors, enriched in cell-cycle regulation pathways. An artificial intelligence-based diagnostic model, utilizing a three-gene panel (MET, PCDHGA3, FAM3C), was developed and validated to identify this fusion. This robust molecular signature could facilitate the identification and stratification of sGBM patients positive for the PTPRZ1-MET fusion.

This retrospective multicenter Canadian study investigated treatment patterns and outcomes in 116 patients with high-risk WHO grade 2 diffuse glioma, treated with radiotherapy and adjuvant alkylating chemotherapy (temozolomide or PCV). Favorable overall survival and progression-free survival rates were observed, with 5-year rates of 94.1% and 77.9% respectively. IDH mutational status emerged as the dominant independent prognostic factor. While no significant difference in progression-free survival was found between temozolomide and PCV in IDH-mutant patients, PCV was associated with higher hematologic toxicity and more dose modifications.